The increased awareness and discussion around more effective weight management medications has resulted in obesity medication pipeline growth. Research and development is focusing on new dosage forms, oral versus injectable, and combinations with glucagon-like peptide-1 receptor agonists. Currently, Eli Lilly and Company (Lilly) and Novo Nordisk dominate the pipeline for weight management medications.
| Product | Manufacturer | Route | Frequency | Class | Maximum Average Weight Loss (Timeframe) | Expected Approval |
|---|---|---|---|---|---|---|
| tirzepatide | Lilly | SC | Once weekly | GLP-1 receptor agonist | 13.4% (72 weeks) |
Late 2023 - Early 2024 |
| semaglutide | Novo Nordisk | Oral | Once daily | GLP-1 receptor agonist | 15.1% (68 weeks) |
2024 |
| CagriSema (cagrilintide/semaglutide) | Novo Nordisk | SC | Once weekly | Amylin analog/GLP-1 receptor agonist | 15.6% (32 weeks) |
2025 |
| danuglipron | Pfizer | Oral | Twice daily | GLP-1 receptor agonist | -5.4kg (12 weeks) |
2025 |
| retatrutide | Lilly | SC | Once weekly | GIP/GLP-1/Glucagon receptor agonist |
17.5% 24.2% |
2026+ |
| orforglipron | Lilly | Oral | Once daily | GLP-1 receptor agonist | 14.7% (36 weeks) |
2026+ |
Reference source: https://www.clinicaltrialsarena.com/features/obesity-trials-to-watch/
